Abstract
ATP-sensitive potassium (“KATP”) channels are rapidly inhibited by intracellular ATP. This inhibition plays a crucial role in the coupling of electrical activity to energy metabolism in a variety of cells. The KATP channel is formed from four each of a sulfonylurea receptor (SUR) regulatory subunit and an inwardly rectifying potassium (Kir6.2) pore-forming subunit. We used systematic chimeric and point mutagenesis, combined with patch-clamp recording, to investigate the molecular basis of ATP-dependent inhibition gating of mouse pancreatic β cell KATP channels expressed in Xenopus oocytes. We identified distinct functional domains of the presumed cytoplasmic C-terminal segment of the Kir6.2 subunit that play an important role in this inhibition. Our results suggest that one domain is associated with inhibitory ATP binding and another with gate closure.
The ATP-sensitive potassium (KATP) channel couples membrane electrical activity to energy metabolism in a variety of cells and is important in several physiological systems. In pancreatic β cells, for example, it is essential for coupling the rate of insulin release to blood glucose levels. Although the channel’s name reflects its characteristic inhibition by intracellular ATP, little is known about the molecular nature of this property.
To understand the molecular mechanisms underlying ATP-dependent inhibition gating in the KATP channel, one must identify those parts of the channel complex that form the ATP-binding site, the inhibition gate, and the “linkage” domains handling signal flow between them. The KATP channel is assembled from four each of two subunit types, a regulatory sulfonylurea receptor (SUR) or SUR1 and a potassium pore-forming subunit or Kir6.2 (1–4). SUR1 is a member of the ATP-binding cassette (ABC) family of proteins featuring two cytoplasmic nucleotide-binding folds, viewed initially as likely mediators of inhibition by ATP (5, 6). However, a mutant Kir6.2 in which the C-terminal 26 residues are deleted remarkably gives rise to potassium channels that retain much ATP sensitivity in the absence of SUR1 (7). The truncation does, however, diminish ATP sensitivity of the KATP channel 10-fold, as does SUR2 when coexpressed with wild-type Kir6.2 (6). These results have led to opposing models in which ATP acts either on Kir6.2 or on SUR to inhibit the KATP channel.
We tested whether major components of the ATP-dependent inhibition gating mechanism reside in the pore-forming subunit. By systematically mutating Kir6.2, we localized molecular components of ATP-dependent inhibition gating to distinct regions of its cytoplasmic C-terminal segment. Our results confirm and extend the findings of Tucker et al. (7) that the primary site of action of inhibitory ATP lies on Kir6.2. We go on to show that one of the regions we identified is likely associated with inhibitory ATP binding, whereas a second region appears to be associated with inhibition gate closure.
MATERIALS AND METHODS
Molecular Biology.
Cloning of mouse SUR1 and Kir6.2 from βHC9 cells. Mouse pancreatic βHC9 cells (8, 9) grown in DMEM with 10% fetal calf serum and 30 mM glucose were a kind gift from the Diabetes Center at the University of Pennsylvania. Total RNA was isolated with a Fast RNA Green Kit (Bio 101) as specified by the supplier. Briefly, 107 cells were placed with extraction buffer into a tube and homogenized in a FastPrep machine (FP120, Savant). This step was followed by several steps of phenol/chloroform extraction and 2-propanol precipitation. For mouse SUR1, total RNA was used for reverse transcription–PCR by using oligonucleotides based on the hamster SUR1 (5) as gene-specific primers. A full-length clone that expressed functional SUR1 was sequenced. For mouse Kir6.2, the same approach was used with gene-specific primers initially based on Kir6.1 (10) and later based on Kir6.2 from the MIN6 cell line (1).
Site-directed mutagenesis.
Preparation of cRNA and site-directed mutagenesis were as described (11). All mutations were confirmed by DNA sequencing.
Electrophysiology.
Preparation and injection of Xenopus oocytes, patch pipet fabrication, and recording techniques were as described (11). Macroscopic and single-channel currents were recorded at −80 mV with the inside-out patch configuration unless indicated otherwise. Pipet solution (mM): 150 KCl, 10 NaCl, 1 CaCl2, 10 EGTA, and 10 Hepes, pH 7.4 ± 0.05. Bath solution: same as pipet solution but with 1.3 MgATP. Constant perfusion of the cytoplasmic face of patches was performed by using either a six-sewer pipe syringe-pressurized system (custom made) or the DAD-12 superfusion system (Adams–List, Westbury, NY). Recordings were always begun within 1 min after excision with the patch pipet partially inserted into one of the sewer pipes. ATP was added as the magnesium salt to minimize rundown, and no other modulatory ligands were added until after the ATP dose-response data were obtained. Experiments showing “rundown” (13), observed as a sudden and significant decrease in channel open probability, PO, were terminated and not used. Patch clamp currents were amplified with an Axopatch 200A (Axon Instruments, Foster City, CA) or EPC-9 (HEKA Electronics, Lambrecht/Pfalz, Germany), low-pass filtered with an 8-pole Bessel filter (Frequency Devices, Haverhill, MA) at a corner frequency of 2 or 4 kHz, and sampled at 20 kHz by using heka pulse version 8.0 (HEKA Electronics). Leak currents (as determined after complete rundown or inhibition with saturating tolbutamide or ATP) were typically 10 pA, always ≤5% of the macroscopic KATP currents, and were not subtracted from the data. Unless indicated otherwise, these recording conditions were used.
Data Analysis.
Analysis and display were done by using tac version 3.0.3 (Bruxton, Seattle, WA), igor pro version 3.01 (WaveMetrics, Lake Oswego, OR), and pagemaker version 6.5 (Adobe Systems, San Jose, CA). Dose-response measurements were fit to the Hill equation, I/Imax = 1/{1 + ([ATP]/Ki)αH}, where [ATP] is the concentration of ATP and I/Imax is the fractional current at the indicated [ATP] relative to that in the same solution in the absence of added ATP. The inhibition constant, Ki, is the [ATP] at which inhibition is one-half maximal, and αH is the slope factor or Hill coefficient. Imax measurements taken before and after I measurements were averaged. Data are presented as mean ± SEM. For Hill plots of data from mutant KATP channels with very large Ki values, we constrained αH to 1.0. This is reasonable given that when αH was a free variable, αH = 1.0 ± 0.1 for the wild-type channel and αH = 1.0 ± 0.3 for all our less severely affected Ki mutant channels. Single-channel current event duration analysis was done by using tac-fit version 3.0.3 (Bruxton), which uses the transformations of Sigworth and Sine (12) to construct and fit duration histograms.
RESULTS
Mouse SUR1 and Mouse Kir6.2 Coexpressed in Xenopus Oocytes Produces Potassium Currents Inhibited by ATP.
To obtain functional KATP channels formed from species-homologous subunits, we cloned both SUR1 and Kir6.2 from the insulin-secreting βHC9 cell line (8, 9) and coinjected the subunit cRNAs into Xenopus oocytes. Expression of either subunit alone failed to increase membrane potassium conductance. Fig. 1A shows a representative example of currents from the cloned KATP channels in inside-out patches in symmetrical 150 mM potassium solutions at −80 mV. The current almost was fully inhibited by internal [ATP] at concentrations above 500 μM and was approximately one-half maximal at 10 μM ATP. At low [ATP], here 0.1 μM, the KATP current decreased significantly over tens of seconds, in a complex process called “rundown” (13). The apparent dissociation constant for inhibition by ATP (Ki) was 12.3 ± 3.5 μM with a Hill coefficient (αH) of 1.03 ± 0.10 (n = 8 oocytes; Fig. 1B). Single channel experiments (Fig. 1C) showed multiple openings in rapid succession separated by long-lived closed times, and these bursting gating kinetics were more conspicuous at negative voltages. In the absence of ATP, there was a single voltage-independent short “intraburst” closed time, whereas open times became shorter in the negative voltage range. Between −40 and −100 mV the open state dwell times at a given voltage were well fit by single exponentials. At −80 mV, the mean open time was 1.85 ± 0.23 ms and the mean intraburst closed time was 0.42 ± 0.22 ms (n = 10). In the absence of ATP, longer duration (“interburst”) closed events were relatively rare. ATP did not obviously affect the open and intraburst closed durations. Rather, it reduced the channel open probability, PO, by shortening the burst durations with single exponential kinetics and lengthening the interburst (inhibition) dwell times in a concentration-dependent manner. A simple model for these ATP-dependent gating kinetics is one in which binding of a single ATP molecule inhibits the KATP channel, and binding of additional ATP molecules further stabilizes the inhibited conformation (14, 15). Analysis of the single-channel current–voltage relationship in symmetrical 150 mM potassium solutions and over the negative voltage range yielded a slope conductance of 79 ± 3 pS (n = 10). These properties of the cloned mouse KATP channel expressed in oocytes are similar to those of the pancreatic β cell KATP channel in its native environment (16–18). The 390-aa residue sequence of Kir6.2 cloned from βHC9 cells is identical to that of the original Kir6.2 cloned from MIN6 cells at the protein level and nearly identical at the DNA level (1). The 1,582 residue sequence of the mouse SUR1 is 95.3% identical to that of hamster, 98.8% identical to that of rat, and 95.6% identical to that of human (5).
Cytoplasmic N-terminal Domain of Kir6.2 Is Unlikely To Be a Major Determinant of ATP Sensitivity of the KATP Channel.
We tested for a role of the presumed cytoplasmic domains of Kir6.2 in ATP sensitivity of the KATP channel because cytoplasmic but not external ATP inhibits the channel (17, 18) and cytoplasmic but not external mild trypsin treatment diminishes ATP sensitivity (19–21). We mutated Kir6.2 rather than SUR1 for several reasons. First, inhibition of the KATP channel does not require hydrolyzable ATP whereas regulation of the cystic fibrosis transmembrane conductance regulator (CFTR), another ABC-channel protein, does (see below). Second, Tucker et al. had demonstrated that deletion of the C-terminal 26 residues of Kir6.2 yields channels that retain substantial ATP sensitivity in the absence of SUR1 (7). Finally, mutations of several residues in both nucleotide-binding folds of SUR, designed to impair or abolish nucleotide binding or hydrolysis, had failed to affect inhibition of KATP channels by ATP (22–24). These earlier findings suggest that molecular components for ATP inhibition gating are in the cytoplasmic domains of Kir6.2. We therefore systematically swapped the cytoplasmic N- and C-terminal domains of Kir6.2 with their counterparts from Kir1.1, which forms potassium channels that are not inhibited by ATP (25). Chimeric constructs were made of Kir6.2 and Kir1.1, with junctions within the transmembrane segments M1 or M2 (Fig. 2). Replacing the N-terminal 73 residues of Kir6.2 with the corresponding residues of Kir1.1 and coexpressing with SUR1 failed to alter ATP sensitivity substantially: this “1.1–6.2–6.2” chimeric channel had a Ki of 30 ± 5 μM (n = 4), a modest 2.5-fold reduction in ATP sensitivity compared with Kir6.2. The reciprocal 6.2–1.1–1.1 chimera, in which the N-terminal 75 residues of Kir6.2 replaced the corresponding residues of Kir1.1, when coexpressed with SUR1 was indistinguishable from Kir1.1, exhibiting no ATP sensitivity (n = 5). These results suggest that the N-terminal cytoplasmic domain of Kir6.2 is not a major determinant of the ATP-dependent inhibition gating of the KATP channel.
Distinct Regions of the Cytoplasmic C-Terminal Domain of Kir6.2 Are Required For Wild-Type ATP Sensitivity.
Next, we explored the presumed cytoplasmic C-terminal domain of Kir6.2. Twelve chimeric constructs, in which all or large parts of the domain were exchanged for corresponding parts from other Kir subunits, failed to yield functional potassium channels when coexpressed with SUR1. However, constructs in which only one or a few C-terminal domain residues of Kir6.2 were replaced by the corresponding residues of Kir1.1, Kir2.1, Kir4.1, or Kir6.1 were functional. Large decreases in ATP sensitivity were observed when the four-residue sequence 334GNTI337 of Kir6.2 was replaced by that of Kir4.1 (26, 27) or Kir2.1 (28) (Fig. 3). The “Kir6.2∷4.1[334–337]” chimera coexpressed with mouse SUR1 always gave rise to potassium channel activity in the cell-attached configuration that, after patch excision into the inside-out configuration, was virtually refractory to [ATP] as high as 2,000 μM. We also studied this construct at the macroscopic current level. Because it is largely resistant to ATP, in three experiments we simply alternated application of 0.1 and a maximal 5,000 μM ATP to the internal face of the channels (Fig. 3A). We found Ki >10,000 μM (n = 8; αH was constrained to 1.0, see Materials and Methods), a >1,000-fold loss of ATP sensitivity (Fig. 3B). Further analysis showed that the G334D substitution accounted for nearly the entire 1,000-fold effect, N335Q had only a 2-fold effect, and T336V and I337V were without effect. Of the other chimeras of this region, the Kir6.2∷2.1[334–337] channel had a Ki of 520 ± 20 μM (n = 4; αH = 1.1 ± 0.1), a >40-fold decrease in ATP sensitivity, whereas the remaining chimeras were similar to Kir6.2 (n = 4), exhibiting strong ATP sensitivity. These results demonstrate that the 334–337 region of Kir6.2 is required for wild-type ATP sensitivity.
A second region of Kir6.2 that is required for wild-type ATP sensitivity of the KATP channel also was identified. When coexpressed with SUR1, Kir6.2∷T171A exhibited a Ki of 500 ± 41 μM (n = 4) and Kir6.2∷I182Q a Ki >10,000 μM (n = 12; Fig. 4). We tested 12 additional mutants of Kir6.2, which when coexpressed with SUR1 gave rise to functional channels. None of the 12 mutations, which were spaced across the region from K207 to S327 (K207Q, K222Q, H234D, G243D, G243V, G245V, N247D, E241G, V244S, A253S, T293D, and S327K), had a substantial effect on ATP sensitivity. Taken together, these findings indicate that at least two regions of Kir6.2, residues 171–182 and residues 334–337, are required for wild-type ATP sensitivity of the KATP channel. Next, we provide evidence that a residue of the former region acts as if it is involved in inhibition gate closure and a residue of the latter in inhibitory ATP binding.
Regions of the Channel Required for ATP-Dependent Inhibition Gate Closure and for ATP Binding.
The truncated subunit Kir6.2ΔC26 (Kir6.2Δ365–390), expressed in the absence of SUR, generates potassium channels retaining much ATP sensitivity (7). We observed, however, important differences from wild-type channels (Fig. 5). The truncated channel (Fig. 5A) exhibited an obviously lowered PO: Immediately following patch excision into ATP-free solution, PO was 0.12 ± 0.02 (n = 5) compared with 0.70 ± 0.14 (n = 5) for wild-type. The truncated channels also exhibited characteristic “spiking” single-channel gating kinetics in the absence of ATP. The spiking kinetics, which differ dramatically from the long bursts typical of wild-type channels, results from a considerable shortening of burst durations (i.e., an increased rate of entry into long-lived interburst closed states). To account for these kinetics we hypothesize that the truncated channel, in the absence of ATP, spontaneously undergoes transitions into long-lived closed conformations, very similar to the ATP-inhibited conformations of the wild-type channel. We recall a remarkable property of ATP-inhibited conformations of the wild-type KATP channel is that their dwell times are [ATP] dependent (14, 15). We found that this still holds for the truncated channel: In the absence of ATP the long-lived closed times largely followed a single exponential distribution with a 14.2 ± 1.3 ms mean dwell time (n = 4; Fig. 5); in 500 μM ATP the mean dwell times increased to 26.3 ± 3.5 ms (n = 4) and in 1,000 μM ATP to 82.6 ± 9.5 ms (n = 4). Mean dwell times of the single open state and of the short-lived intraburst closed state remained, as in wild-type, largely unaffected by ATP.
According to our hypothesis, a mutation that disrupts the channel’s ATP sensitivity by preventing gate closure (an action subsequent to ATP binding) also could be expected to prevent the spontaneous entry of truncated channels into long-lived closed states. In this case, such a mutation should restore wild-type bursting kinetics in truncated channels in the absence of ATP. Conversely, a mutation that affects only ATP binding need not be expected to prevent spontaneous entry of the truncated channel into the inhibited state in the absence of ATP. In this case, such a mutation should preserve the spiking kinetics of truncated channels. To test these predictions, we combined mutations in either the 171–182 region or the 334–337 region with the ΔC26 truncation and expressed these double-mutant channels in the absence of SUR1.
We found that T171A dramatically converts the spiking kinetics of ΔC26 back to long bursting kinetics (Fig. 6). In the absence of SUR and with little or no ATP present, the T171A/ΔC26 double mutant channel shows the long bursting kinetics typical of the wild-type KATP channel observed under the same experimental conditions (n = 10/10). Still in the absence of SUR, the double mutant channel remained refractory to ATP inhibition (n = 5), demonstrating that the loss of ATP sensitivity caused by T171A is not somehow mediated by SUR1. We therefore propose that the T171A mutation affects gating transitions downstream from those associated with ATP binding. A plausible interpretation is that T171A disrupts conformational transitions required for inhibition gate closure. On the other hand, the G334D (n = 4/4) and 4.1[334–337] (n = 4/4) mutations in the truncated channel failed to restore the long bursting kinetics in the absence of ATP. The G334D/ΔC26 and 4.1[334–337]/ΔC26 double mutant channels, however, remained refractory to ATP inhibition. These results support our interpretation that the 334–335 region is required for steps preceding gate closure, presumably those associated with ATP binding per se (see below).
DISCUSSION
Our results suggest a molecular mechanism in which C-terminal residues of Kir6.2 are associated with distinct functional domains of the ATP-dependent inhibition gating mechanism. For example, the Kir6.2 sequence 333FGNTIK338, which we identify here as a likely component of the ATP-binding site, includes an ATP-binding motif FX4K that is highly conserved in the intracellular ATP-binding loop of ion-motive ATPases (29). Although both are sensitive to μM ATP, neither Kir6.2 nor ion-motive ATPases contain Walker-type ATP-binding motifs. Our proposal that the 333–338 region of Kir6.2 is part of the inhibitory ATP-binding site also is consistent with the failure of G334D- and 4.1[334–337]-mutated Kir6.2ΔC26 channels to revert from spiking single-channel kinetics to long bursting kinetics similar to wild-type.
The proposal that the region including T171 of Kir6.2 participates in inhibition gating is supported by the ability of the T171A mutation to convert the spiking single-channel kinetics of truncated Kir6.2ΔC26 channels back to wild-type bursting kinetics. Our mutagenesis in this region, including detailed analysis of T171A on the ΔC26 background, now suggests it is required for inhibition gate closure. Shyung et al. (24) have shown moderate effects of substitutions at position 160 in the M2 region on ATP sensitivity. Residues 160–171, which span part of the second transmembrane domain M2 and the initial cytoplasmic C-terminal segment, are therefore likely to participate in gating. Interestingly, mutant analysis of the homologous position in the Shaker potassium channel implicates its involvement in voltage-dependent activation–deactivation gating (30). We expect further studies to reveal additional shared properties between deactivation gating in Shaker and inhibition gating in KATP channels.
Our finding confirms and extends the report of Tucker et al. (7) that truncation of Kir6.2 yields channels that remain ATP sensitive in the absence of SUR. Tucker et al. also reported that mutation of a single C-terminal residue K185Q, on the Kir6.2ΔC26 background, decreases by 40-fold sensitivity to inhibition by ATP. We also found that mutation I182Q, on the wild-type Kir6.2 background, decreases by >1,000-fold inhibition gating by ATP. The proximity of I182 to K185 may suggest a common role for these two residues in ATP-dependent inhibition gating. It will be interesting to determine the single- channel gating behavior of these and other mutations on the ΔC26 background in the absence of SUR and ATP.
Our findings fit well with the observation that numerous mutations in either or both nucleotide-binding folds of SUR fail to alter ATP-dependent inhibition gating of the KATP channel (22–24). Mutations in the nucleotide-binding folds of the SUR subunit can disrupt stimulation by MgADP and sensitivity to potassium channel openers, with little or typically no effect on ATP inhibition. The nucleotide-binding folds of ABC proteins have been generally associated with ATP hydrolysis-dependent functions. For example, in CFTR, ATP hydrolysis at one nucleotide-binding fold is required for opening of the chloride conduction pathway, whereas hydrolysis at the other is required for closure (31–35). When both ATP and its nonhydrolyzable analog adenosine-5′-(β,γ-imido)triphosphate (AMP-PNP) are present, the latter can bind to an open channel’s nucleotide-binding fold and prevent closure, producing CFTR channels with extraordinarily extended burst times. In the case of the KATP channel, however, AMP-PNP and ATP each inhibit conductance with comparable efficacy, suggesting that no hydrolysis is required (17, 18, 36). Major molecular components required for ATP inhibition of the KATP channel rather reside in distinct functional domains of the cytoplasmic C-terminal segment of Kir6.2 that we identify in the present study.
Any molecular model for ATP-dependent inhibition gating must account for signal flow from ATP binding per se to closure of a gate during inhibition and from ATP unbinding to opening of the gate during recovery. In the present study, we show that residues 333–338 look and behave as if they are part of an ATP-binding domain. In view of the multimeric structure proposed for the KATP channel (2–4), our results suggest that each Kir6.2 subunit might contribute a functional ATP-binding site to the KATP channel. Such multiple sites could readily explain the ATP concentration dependence of the long-lived closed times of both the native KATP channel (14, 15) and the truncated Kir6.2ΔC26 channel (shown here).
Acknowledgments
The authors gratefully acknowledge Rick Aldrich, Clay Armstrong, Steve Baylor, and Franz Matschinsky for critical discussions, Paul DeWeer and Robin Post for critical reading of the manuscript, and Chris Engle for excellent technical assistance. This work was supported by grants from the Research Foundation of the University of Pennsylvania and a National Institutes of Health Pilot Project grant from the Diabetes Center of the University of Pennsylvania. During the course of this work, Lehong Li was a National Research Service Award (HL 07207) postdoctoral fellow and Peter Drain was a faculty fellow of the McCabe Foundation.
ABBREVIATIONS
- PO
channel open probability
- SUR
sulfonylurea receptor
- ABC
ATP-binding cassette
References
- 1.Inagaki N, Gonoi T, Clement J P, IV, Namba N, Inazawa J, Gonzalez G, Aguilar-Bryan L, Seino S, Bryan J. Science. 1995;270:1166–1170. doi: 10.1126/science.270.5239.1166. [DOI] [PubMed] [Google Scholar]
- 2.Clement J P, IV, Kunjilwar K, Gonzales G, Schwanstecher M, Panten U, Aguilar-Bryan L, Bryan J. Neuron. 1997;18:827–838. doi: 10.1016/s0896-6273(00)80321-9. [DOI] [PubMed] [Google Scholar]
- 3.Inagaki N, Gonoi T, Seino S. FEBS Lett. 1997;409:232–236. doi: 10.1016/s0014-5793(97)00488-2. [DOI] [PubMed] [Google Scholar]
- 4.Shyng S-L, Nichols C G. J Gen Physiol. 1997;110:655–664. doi: 10.1085/jgp.110.6.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Aguilar-Bryan L, Nichols C G, Wechsler S W, Clement J P T, IV, Boyd A E, Gonzalez G, Herrera-Sosa H, Nguy K, Bryan J, Nelson D A. Science. 1995;268:423–426. doi: 10.1126/science.7716547. [DOI] [PubMed] [Google Scholar]
- 6.Inagaki N, Gonoi T, Clement J P, IV, Wang C-Z, Aquilar-Bryan L, Bryan J, Seino S. Neuron. 1996;16:1011–1017. doi: 10.1016/s0896-6273(00)80124-5. [DOI] [PubMed] [Google Scholar]
- 7.Tucker S J, Gribble F M, Zhao C, Trapp S, Ashcroft F M. Nature (London) 1997;387:179–183. doi: 10.1038/387179a0. [DOI] [PubMed] [Google Scholar]
- 8.Liang Y, Bai G, Doliba N, Buettger C, Wang L, Berner D K, Matschinsky F M. Am J Physiol. 1996;270:E846–E857. doi: 10.1152/ajpendo.1996.270.5.E846. [DOI] [PubMed] [Google Scholar]
- 9.Radvanyi F, Christgau S, Baekkeskov S, Jolicoeur C, Hanahan D. Mol Cell Biol. 1993;13:4223–4232. doi: 10.1128/mcb.13.7.4223. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Inagaki N, Tsuura Y, Namba N, Masuda K, Gonoi T, Horie M, Seino Y, Mizuta M, Seino S. J Biol Chem. 1995;270:5691–5694. doi: 10.1074/jbc.270.11.5691. [DOI] [PubMed] [Google Scholar]
- 11.Drain P, Dubin A, Aldrich R W. Neuron. 1994;12:1097–1109. doi: 10.1016/0896-6273(94)90317-4. [DOI] [PubMed] [Google Scholar]
- 12.Sigworth F J, Sine S M. Biophys J. 1987;48:149–158. doi: 10.1016/S0006-3495(87)83298-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Trube G, Hescheler J. Pflügers Arch. 1984;401:178–184. doi: 10.1007/BF00583879. [DOI] [PubMed] [Google Scholar]
- 14.Qin D, Takano M, Noma A. Am J Physiol. 1989;257:H1624–H1633. doi: 10.1152/ajpheart.1989.257.5.H1624. [DOI] [PubMed] [Google Scholar]
- 15.Nichols C G, Lederer W J, Cannell M B. Biophys J. 1991;60:1164–1177. doi: 10.1016/S0006-3495(91)82152-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Ashcroft F M, Harrison D E, Ashcroft S J H. Nature (London) 1984;312:446–448. doi: 10.1038/312446a0. [DOI] [PubMed] [Google Scholar]
- 17.Cook D L, Hales C N. Nature (London) 1984;311:271–273. doi: 10.1038/311271a0. [DOI] [PubMed] [Google Scholar]
- 18.Ashcroft F M. Annu Rev Neurosci. 1988;11:97–118. doi: 10.1146/annurev.ne.11.030188.000525. [DOI] [PubMed] [Google Scholar]
- 19.Proks P, Ashcroft F M. Pflügers Arch. 1993;424:63–72. doi: 10.1007/BF00375103. [DOI] [PubMed] [Google Scholar]
- 20.Lee K, Ozanne S, Rowe I, Hales C, Ashford M. Mol Pharmacol. 1994;45:176–185. [PubMed] [Google Scholar]
- 21.Deutsch N, Weiss J N. Am J Physiol. 1994;266:H613–H622. doi: 10.1152/ajpheart.1994.266.2.H613. [DOI] [PubMed] [Google Scholar]
- 22.Nichols C G, Shyng S-L, Nestorowicz A, Glaser B, Clement J P, IV, Gonzales G, Aguilar-Bryan L, Permutt M A, Bryan J. Science. 1996;272:1785–1787. doi: 10.1126/science.272.5269.1785. [DOI] [PubMed] [Google Scholar]
- 23.Gribble F M, Tucker S J, Ashcroft F M. EMBO J. 1997;16:1145–1152. doi: 10.1093/emboj/16.6.1145. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Shyng S-L, Ferrigni T, Nichols C G. J Gen Physiol. 1997;110:643–654. doi: 10.1085/jgp.110.6.643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Ho K, Nichols C G, Lederer W J, Lytton J, Vassilev P M, Kanazirska M V, Hebert S C. Nature (London) 1993;362:31–38. doi: 10.1038/362031a0. [DOI] [PubMed] [Google Scholar]
- 26.Bredt D S, Wang T L, Cohen N A, Guggino W B, Snyder S H. Proc Natl Acad Sci USA. 1995;92:6753–6757. doi: 10.1073/pnas.92.15.6753. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Takumi T, Ishii T, Horio Y, Morishige K, Takahashi N, Yamada M, Yamashita T, Kiyama H, Sohmiya K, Nakanishi S, et al. J Biol Chem. 1995;270:16339–16346. doi: 10.1074/jbc.270.27.16339. [DOI] [PubMed] [Google Scholar]
- 28.Kubo Y, Baldwin E T J, Jan Y-N, Jan L-Y. Nature (London) 1993;362:127–133. doi: 10.1038/362127a0. [DOI] [PubMed] [Google Scholar]
- 29.McIntosh D B, Woolley D G, Vilsen B, Andersen J P. J Biol Chem. 1996;271:25778–25789. doi: 10.1074/jbc.271.42.25778. [DOI] [PubMed] [Google Scholar]
- 30.Liu Y, Holmgren M, Jurman M E, Yellen G. Neuron. 1997;19:175–184. doi: 10.1016/s0896-6273(00)80357-8. [DOI] [PubMed] [Google Scholar]
- 31.Baukrowitz T, Hwang T C, Nairn A C, Gadsby D C. Neuron. 1994;12:473–482. doi: 10.1016/0896-6273(94)90206-2. [DOI] [PubMed] [Google Scholar]
- 32.Hwang T C, Nagel G, Nairn A C, Gadsby D C. Proc Natl Acad Sci USA. 1994;91:4698–4702. doi: 10.1073/pnas.91.11.4698. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Gunderson K L, Kopito R R. J Biol Chem. 1994;269:19349–19353. [PubMed] [Google Scholar]
- 34.Gunderson K L, Kopito R R. Cell. 1995;82:231–239. doi: 10.1016/0092-8674(95)90310-0. [DOI] [PubMed] [Google Scholar]
- 35.Gadsby D C, Nagel G, Hwang T C. Annu Rev Physiol. 1995;57:387–416. doi: 10.1146/annurev.ph.57.030195.002131. [DOI] [PubMed] [Google Scholar]
- 36.Ohno-Shosaku T, Zunckler B J, Trube G. Pflügers Arch. 1987;408:133–138. doi: 10.1007/BF00581342. [DOI] [PubMed] [Google Scholar]